Overview

Immuno Oncology Assays Market is poised to value USD 9998.44 million by 2028 end at a CAGR of 12.5% during the forecast period 2022 to 2028.

Increase in the incidence of cancer, advancements in technology particularly in molecular techniques, extensive research undertaken and development in cancer diagnostics, and ongoing clinical trials in cancer immunotherapy is expected to accelerate the immuno oncology assays market. According to the World Health Organization (WHO), cancer accounted for 8.8 million deaths worldwide. One out of six deaths is due to cancer. Hence, an increase in the prevalence of cancer and the rising need for personalized medicine is expected to drive the immune oncology assays market during the forecast period. With the introduction of highly sensitive molecular techniques such as next-generation sequencing (NGS) and digital PCR (dPCR), researchers and clinicians can analyze various circulating biomarkers. These innovative technologies provide an economical and minimally invasive way for diagnosis, prognosis, and therapy selection in patients throughout their treatment plan thus bolstering the market worldwide.

Based on technology, the Immuno-Oncology Assays Market is segmented into PCR, immunoassay, NGS, flow cytometry, and other technologies. The NGS segment is estimated to be the segment growing with the highest CAGR during the forecast period. The integration of economical costs and advanced NGS technologies, rising government funding for sequencing projects, growing adoption of high-throughput sequencing technologies in emerging economies, and new product launches in immuno-oncology biomarker discovery are some of the key factors propelling the growth of the NGS segment.

On the basis of application, the Immuno-Oncology Assays Market is segmented into research applications and clinical diagnostics. Research applications dominated the market by holding the major market share. It is also forecasted to be the fastest-growing segment during the forecast period. The rising prominence of biomarker-based drug development and clinical trials and the emergence of cancer immunotherapy are the key factors driving market growth.

Based on region, North America and Europe are expected to be major markets for the immuno oncology assays market. Sound health care infrastructure and funding from public and private sectors for research and development are projected to fuel the market in these regions. According to the American Cancer Society, an estimated 1,735,350 new cancer cases will be diagnosed and 609,640 cancer deaths will occur in the U.S. Asia Pacific is expected to account for a significant share of the market during the forecast period. Federal support and innovation of novel therapeutics in the field of cancer is anticipated to drive the market in the region.

Major players included in the Immuno Oncology Assays Market:
• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Agilent Technologies, Inc.
• Illumina, Inc.
• NanoString Technologies, Inc.
• Sartorius AG
• HTG Molecular Diagnostics, Inc.
• QIAGEN N.V.
• Merck Millipore
• PerkinElmer, Inc.
• Abbott Laboratories, Inc.
• Guardant Health, Inc.
• bioMérieux SA
• Myriad Genetics, Inc.
• Bio-Rad Laboratories, Inc.
• Charles River Laboratories, Inc.
• Creative Biolabs
(Note: The list of the major players will be updated with the latest market scenario and trends)

Market Segmentation:

By Product
• Consumables
• Instruments
• Software & Services

By Technology
• PCR
• Immunoassay
• NGS
• Flow Cytometry
• ISH
• Other Technologies

By Indication
• Lung Cancer
• Colorectal Cancer
• Melanoma
• Bladder Cancer
• Other Cancers

By Application
• Research Applications
• Clinical Diagnostics

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Biopharmaceuticals Market by product, by technology, by indication by application and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com